ATE454378T1 - Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen - Google Patents
Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignenInfo
- Publication number
- ATE454378T1 ATE454378T1 AT03778092T AT03778092T ATE454378T1 AT E454378 T1 ATE454378 T1 AT E454378T1 AT 03778092 T AT03778092 T AT 03778092T AT 03778092 T AT03778092 T AT 03778092T AT E454378 T1 ATE454378 T1 AT E454378T1
- Authority
- AT
- Austria
- Prior art keywords
- jak
- inhibitors
- protein kinases
- compounds active
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42297302P | 2002-11-01 | 2002-11-01 | |
| PCT/US2003/034991 WO2004041789A1 (en) | 2002-11-01 | 2003-11-03 | Compositions useful as inhibitors of jak and other protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE454378T1 true ATE454378T1 (de) | 2010-01-15 |
Family
ID=32312580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03778092T ATE454378T1 (de) | 2002-11-01 | 2003-11-03 | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7312227B2 (de) |
| EP (2) | EP1562911B1 (de) |
| JP (2) | JP2006512314A (de) |
| AT (1) | ATE454378T1 (de) |
| AU (2) | AU2003286876A1 (de) |
| CA (1) | CA2506772A1 (de) |
| DE (1) | DE60330895D1 (de) |
| WO (1) | WO2004041789A1 (de) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| IL166241A0 (en) * | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| AU2003262642B2 (en) * | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| US7348335B2 (en) * | 2002-11-05 | 2008-03-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| EP1626962B1 (de) * | 2003-05-12 | 2007-02-28 | Pfizer Products Inc. | Benzamidinhibitoren des p2x7-rezeptors |
| ES2421139T3 (es) * | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| EP1648875A1 (de) * | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidine als kinaseinhibitoren |
| US7037927B2 (en) * | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| PT1689715E (pt) * | 2003-12-03 | 2011-05-16 | Ym Biosciences Australia Pty | Inibidores da tubulina |
| WO2006032851A1 (en) * | 2004-09-20 | 2006-03-30 | Biolipox Ab | Pyrazole compounds useful in the treatment of inflammation |
| WO2006032852A1 (en) * | 2004-09-20 | 2006-03-30 | Biolipox Ab | Pyrazole compounds useful uin the treatment of inflammation |
| US7799915B2 (en) * | 2004-10-13 | 2010-09-21 | Wyeth Llc | Anilino-pyrimidine analogs |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| PL1836169T3 (pl) | 2004-12-28 | 2012-07-31 | Kinex Pharmaceuticals Llc | Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| JP2008540436A (ja) * | 2005-05-03 | 2008-11-20 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jakキナーゼインヒビターおよびそれらの使用 |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| PL1940786T3 (pl) | 2005-09-16 | 2010-12-31 | Arrow Therapeutics Ltd | Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C |
| TW200800911A (en) * | 2005-10-20 | 2008-01-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
| TW200732320A (en) * | 2005-10-31 | 2007-09-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
| AU2006310367A1 (en) * | 2005-10-31 | 2007-05-10 | Biolipox Ab | Triazole compounds as lipoxygenase inhibitors |
| US20090088463A1 (en) * | 2005-11-01 | 2009-04-02 | Benjamin Pelcman | Pyrazoles Useful in the Treatment of Inflammation |
| EA200870217A1 (ru) | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US7834178B2 (en) * | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
| JP5564251B2 (ja) * | 2006-06-29 | 2014-07-30 | キネックス ファーマシューティカルズ, エルエルシー | キナーゼカスケードを調節するためのビアリール組成物および方法 |
| AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| DK2089369T3 (da) | 2006-10-19 | 2011-05-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme |
| US20080153822A1 (en) * | 2006-11-30 | 2008-06-26 | Martin Augustin | Methods of treating pain |
| US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
| HUE029188T2 (en) * | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| AU2016200866B2 (en) * | 2007-03-12 | 2017-06-22 | Glaxosmithkline Llc | Phenyl amino pyrimidine compounds and uses thereof |
| AU2013201306B2 (en) * | 2007-03-12 | 2015-11-12 | Glaxosmithkline Llc | Phenyl Amino Pyrimidine Compounds and Uses Thereof |
| CL2008000986A1 (es) | 2007-04-06 | 2008-10-17 | Neurocrine Biosciences Inc | COMPUESTO DERIVADO DE HETEROCICLOS DE NITROGENO, AGONISTAS DEL RECEPTOR GnRH; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO PARA TRATAR UNA AFECCION RELACIONADA CON LAS HORMONAS SEXUALES, ENDOMETRIOSIS, DISMENORREA, ENFERMEDAD DE OV |
| MX2009010828A (es) | 2007-04-06 | 2009-10-29 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de gonadotropina y metodos relacionados con los mismos. |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| EP2200436B1 (de) * | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituierte pyrimidinylamine als proteinkinasenhemmer |
| WO2009029998A1 (en) * | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| WO2009034390A1 (en) * | 2007-09-14 | 2009-03-19 | Arrow Therapeutics Limited | Heterocyclic derivatives and their use in treating hepatitis c |
| JP2011506445A (ja) * | 2007-12-13 | 2011-03-03 | アムジエン・インコーポレーテツド | γ−セクレターゼ調節剤 |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| JPWO2009107391A1 (ja) * | 2008-02-27 | 2011-06-30 | 武田薬品工業株式会社 | 6員芳香環含有化合物 |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| BRPI0910668A2 (pt) | 2008-04-22 | 2019-09-24 | Portola Pharmaceutiacals Inc | inibidores de proteína quinases |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| MX337849B (es) * | 2009-07-28 | 2016-03-09 | Rigel Pharmaceuticals Inc | Composiciones y metodos para inhibicion de la via jak. |
| CN107441097A (zh) | 2010-04-16 | 2017-12-08 | 阿西纳斯公司 | 用于预防和治疗癌症的组合物以及方法 |
| EP2975027A1 (de) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamide als jak-kinasemodulatoren |
| WO2012066065A1 (en) * | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| JP5947818B2 (ja) * | 2011-03-02 | 2016-07-06 | リード ディスカバリー センター ゲーエムベーハー | 薬学的活性化二置換ピリジン誘導体 |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| EP2782579B1 (de) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazinkinaseinhibitoren |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| KR20150044952A (ko) * | 2012-08-23 | 2015-04-27 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 신규한 페닐-피리딘/피라진 아미드 |
| US9926273B2 (en) | 2012-08-30 | 2018-03-27 | Athenex, Inc. | Composition and methods for modulating a kinase cascade |
| WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| US9284310B2 (en) | 2012-11-03 | 2016-03-15 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
| RS62649B1 (sr) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| EP3140298A1 (de) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-assoziierte kinaseinhibitoren |
| TWI681954B (zh) | 2014-06-12 | 2020-01-11 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| CN108503583B (zh) * | 2018-05-14 | 2020-10-09 | 江南大学 | 一种含氮氢类化合物的烷基化方法及其应用 |
| US12208098B2 (en) * | 2018-11-26 | 2025-01-28 | Gachon University Of Industry-Academic Cooperation Foundation | 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof |
| KR102540219B1 (ko) * | 2018-11-26 | 2023-06-08 | (의료)길의료재단 | 신규한 4-카보닐아미노-4-페닐피리미딘 화합물 또는 이의 약제학적으로 허용가능한 염 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| WO2020212395A1 (en) | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| CN110330484B (zh) * | 2019-07-18 | 2022-08-26 | 中国药科大学 | 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN112142675B (zh) * | 2020-10-09 | 2021-11-30 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的小分子化合物及其用途 |
| US20250283174A1 (en) | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
| WO2026093435A1 (en) | 2024-10-31 | 2026-05-07 | Institut National de la Santé et de la Recherche Médicale | Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer |
| CN120157658B (zh) * | 2025-03-07 | 2026-01-09 | 辽宁大学 | 含有甲苯结构的氨基嘧啶类化合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| PT672042E (pt) | 1993-10-01 | 2006-08-31 | Novartis Ag | Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao |
| AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| DE69429078T2 (de) | 1993-10-01 | 2002-07-11 | Novartis Ag, Basel | Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| DE69919707T2 (de) | 1998-06-19 | 2005-09-01 | Chiron Corp., Emeryville | Glycogen synthase kinase 3 inhibitoren |
| GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| WO2002020495A2 (en) * | 2000-09-06 | 2002-03-14 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| GB0107901D0 (en) | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
| MXPA03008888A (es) | 2001-03-29 | 2005-03-07 | Vertex Pharma | Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas. |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| US7348335B2 (en) * | 2002-11-05 | 2008-03-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
-
2003
- 2003-11-03 EP EP03778092A patent/EP1562911B1/de not_active Expired - Lifetime
- 2003-11-03 WO PCT/US2003/034991 patent/WO2004041789A1/en not_active Ceased
- 2003-11-03 AU AU2003286876A patent/AU2003286876A1/en not_active Abandoned
- 2003-11-03 JP JP2004550434A patent/JP2006512314A/ja active Pending
- 2003-11-03 DE DE60330895T patent/DE60330895D1/de not_active Expired - Lifetime
- 2003-11-03 EP EP10000022A patent/EP2172460A1/de not_active Withdrawn
- 2003-11-03 US US10/700,333 patent/US7312227B2/en not_active Expired - Fee Related
- 2003-11-03 AT AT03778092T patent/ATE454378T1/de not_active IP Right Cessation
- 2003-11-03 CA CA002506772A patent/CA2506772A1/en not_active Abandoned
-
2010
- 2010-06-18 JP JP2010140019A patent/JP2010229154A/ja active Pending
-
2011
- 2011-01-07 AU AU2011200057A patent/AU2011200057A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011200057A1 (en) | 2011-01-27 |
| JP2006512314A (ja) | 2006-04-13 |
| EP1562911A1 (de) | 2005-08-17 |
| EP1562911B1 (de) | 2010-01-06 |
| WO2004041789A1 (en) | 2004-05-21 |
| EP2172460A1 (de) | 2010-04-07 |
| JP2010229154A (ja) | 2010-10-14 |
| US20040147507A1 (en) | 2004-07-29 |
| US7312227B2 (en) | 2007-12-25 |
| AU2003286876A1 (en) | 2004-06-07 |
| CA2506772A1 (en) | 2004-05-21 |
| DE60330895D1 (de) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60330895D1 (de) | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen | |
| ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| DE60214703D1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
| NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
| ATE425160T1 (de) | Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| IL187438A0 (en) | Pyrrolopyridine derivatives and pharmaceutical compositions containing the same | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| CY1112253T1 (el) | Ενωσεις διαμινοτριαζολιου χρησιμες ως αναστολεις κινασης πρωτεϊνης | |
| HRP20110566T8 (en) | Azaindoles useful as inhibitors of jak and other protein kinases | |
| ATE466581T1 (de) | Verbindungen auf pyrimidin-basis als gsk-3-hemmer | |
| BG108650A (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| MXPA03010961A (es) | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. | |
| DE60214198D1 (de) | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen | |
| NO20045677L (no) | Inhibitorer av JAK- og CDK2-proteinkinaser | |
| WO2004046120A3 (en) | Diaminotriazoles useful as inhibitors of protein kinases | |
| CY1110742T1 (el) | Αναστολεις ινδαζολης, βενζισοξαζολης, και βενζισοθειαζολης | |
| DE602004012578D1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
| DE60205455T2 (de) | Naphthyridinderivate | |
| ATE546452T1 (de) | Pyrazolopyrrolderivate als proteinkinaseinhibitoren | |
| NO20062256L (no) | Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |